The IGF1 titration group had significantly lower height gain ( 0.17 SDS , s.d. 0.18 ) during the second year of the randomised trial compared with the high-dose group ( 0.46 SDS , s.d. 0.25 ) , but not significantly lower than the low-dose group ( 0.23 SDS , s.d. 0.15 ; P = 0.17 ) .